{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33911160", "DateCompleted": {"Year": "2021", "Month": "10", "Day": "22"}, "DateRevised": {"Year": "2024", "Month": "08", "Day": "09"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "04", "Day": "28"}], "Language": ["eng"], "ELocationID": ["9181", "10.1038/s41598-021-88816-1"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "11", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Apr", "Day": "28"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.", "Pagination": {"StartPage": "9181", "MedlinePgn": "9181"}, "Abstract": {"AbstractText": ["The eukaryotic elongation factor-2 kinase, eEF2K, which restricts protein translation elongation, has been identified as a potential therapeutic target for diverse types of malignancies including triple negative breast cancer (TNBC). However, the contexts in which eEF2K inhibition is essential in TNBC and its consequences on the proteome are largely unknown. Here we show that genetic or pharmacological inhibition of eEF2K cooperated with glutamine (Gln) starvation, and synergized with glutaminase (GLS1) inhibitors to suppress growth of diverse TNBC cell lines. eEF2K inhibition also synergized with depletion of eukaryotic translation initiation factor 4E-binding protein 1 (eIF4EBP1; 4EBP1), a suppressor of eukaryotic protein translation initiation factor 4E (eIF4E), to induce c-MYC and Cyclin D1 expression, yet attenuate growth of TNBC cells. Proteomic analysis revealed that whereas eEF2K depletion alone uniquely induced Cyclin Dependent Kinase 1 (CDK1) and 6 (CDK6), combined depletion of eEF2K and 4EBP1 resulted in overlapping effects on the proteome, with the highest impact on the 'Collagen containing extracellular matrix' pathway (e.g. COL1A1), as well as the amino-acid transporter, SLC7A5/LAT1, suggesting a regulatory loop via mTORC1. In addition, combined depletion of eEF2K and 4EBP1 indirectly reduced the levels of IFN-dependent innate immune response-related factors. Thus, eEF2K inhibition triggers cell cycle arrest/death under unfavourable metabolic conditions such as Gln-starvation/GLS1 inhibition or 4EBP1 depletion, uncovering new therapeutic avenues for TNBC and underscoring a pressing need for clinically relevant eEF2K inhibitors."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Max Bell Research Centre, Toronto General Research Institute, University Health Network, 101 College Street, Suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Ju", "ForeName": "YoungJun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province, Chinese Academic of Sciences, Guiyang, 550014, Guizhou, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Program in Cell Biology, The Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada."}], "LastName": "Rotin", "ForeName": "Daniela", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Max Bell Research Centre, Toronto General Research Institute, University Health Network, 101 College Street, Suite 5R406, Toronto, ON, M5G 1L7, Canada. eldad.zacksenhaus@utoronto.ca."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}], "GrantList": [{"Agency": "CIHR", "Country": "Canada"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adaptor Proteins, Signal Transducing"}, {"RegistryNumber": "0", "NameOfSubstance": "Benzeneacetamides"}, {"RegistryNumber": "0", "NameOfSubstance": "CB-839"}, {"RegistryNumber": "0", "NameOfSubstance": "CCND1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Cell Cycle Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Cyclopentanes"}, {"RegistryNumber": "0", "NameOfSubstance": "EIF4EBP1 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Proto-Oncogene Proteins c-myc"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfides"}, {"RegistryNumber": "0", "NameOfSubstance": "TX1918"}, {"RegistryNumber": "0", "NameOfSubstance": "Thiadiazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide"}, {"RegistryNumber": "136601-57-5", "NameOfSubstance": "Cyclin D1"}, {"RegistryNumber": "EC 2.7.1.17", "NameOfSubstance": "EEF2K protein, human"}, {"RegistryNumber": "EC 2.7.11.20", "NameOfSubstance": "Elongation Factor 2 Kinase"}, {"RegistryNumber": "EC 3.5.1.2", "NameOfSubstance": "GLS protein, human"}, {"RegistryNumber": "EC 3.5.1.2", "NameOfSubstance": "Glutaminase"}], "MeshHeadingList": [{"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Adaptor Proteins, Signal Transducing"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Benzeneacetamides"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Cell Cycle Proteins"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cyclin D1"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Cyclopentanes"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": ["antagonists & inhibitors", "genetics"], "DescriptorName": "Elongation Factor 2 Kinase"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Gene Silencing"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Glutaminase"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["analysis", "metabolism"], "DescriptorName": "Proteins"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-myc"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Sulfides"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Thiadiazoles"}, {"QualifierName": ["drug therapy", "genetics", "metabolism", "pathology"], "DescriptorName": "Triple Negative Breast Neoplasms"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Prat A, et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123\u2013133. doi: 10.1634/theoncologist.2012-0397.", "ArticleIdList": ["10.1634/theoncologist.2012-0397", "PMC3579595", "23404817"]}, {"Citation": "Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u2013198. doi: 10.1158/2159-8290.CD-18-1177.", "ArticleIdList": ["10.1158/2159-8290.CD-18-1177", "PMC6387871", "30679171"]}, {"Citation": "Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011;121:2750\u20132767. doi: 10.1172/JCI45014.", "ArticleIdList": ["10.1172/JCI45014", "PMC3127435", "21633166"]}, {"Citation": "Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Sci. Rep. 2019;9:19107. doi: 10.1038/s41598-019-55710-w.", "ArticleIdList": ["10.1038/s41598-019-55710-w", "PMC6911070", "31836816"]}, {"Citation": "Schmid P, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl. J. Med. 2018 doi: 10.1056/NEJMoa1809615.", "ArticleIdList": ["10.1056/NEJMoa1809615", "30345906"]}, {"Citation": "Liu JC, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol. Med. 2014;6:1542\u20131560. doi: 10.15252/emmm.201404402.", "ArticleIdList": ["10.15252/emmm.201404402", "PMC4287974", "25330770"]}, {"Citation": "Wang X, Xie J, Proud CG. Eukaryotic elongation factor 2 kinase (eEF2K) in cancer. Cancers (Basel) 2017;9:162. doi: 10.3390/cancers9120162.", "ArticleIdList": ["10.3390/cancers9120162", "PMC5742810", "29186827"]}, {"Citation": "Leprivier G, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013;153:1064\u20131079. doi: 10.1016/j.cell.2013.04.055.", "ArticleIdList": ["10.1016/j.cell.2013.04.055", "PMC4395874", "23706743"]}, {"Citation": "Delaidelli A, Leprivier G, Sorensen PH. eEF2K protects MYCN-amplified cells from starvation. Cell Cycle. 2017;16:1633\u20131634. doi: 10.1080/15384101.2017.1355180.", "ArticleIdList": ["10.1080/15384101.2017.1355180", "PMC5602424", "28767324"]}, {"Citation": "Delaidelli A, et al. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Cell Death Differ. 2017;24:1564\u20131576. doi: 10.1038/cdd.2017.79.", "ArticleIdList": ["10.1038/cdd.2017.79", "PMC5563988", "28574509"]}, {"Citation": "Hori H, et al. TX-1123: an antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity. Bioorg. Med. Chem. 2002;10:3257\u20133265. doi: 10.1016/s0968-0896(02)00160-8.", "ArticleIdList": ["10.1016/s0968-0896(02)00160-8", "12150871"]}, {"Citation": "Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27\u201355. doi: 10.1016/0065-2571(84)90007-4.", "ArticleIdList": ["10.1016/0065-2571(84)90007-4", "6382953"]}, {"Citation": "Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer. 2016 doi: 10.1038/nrc.2016.71.", "ArticleIdList": ["10.1038/nrc.2016.71", "28704359"]}, {"Citation": "Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010;35:427\u2013433. doi: 10.1016/j.tibs.2010.05.003.", "ArticleIdList": ["10.1016/j.tibs.2010.05.003", "PMC2917518", "20570523"]}, {"Citation": "Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 2014;13:890\u2013901. doi: 10.1158/1535-7163.MCT-13-0870.", "ArticleIdList": ["10.1158/1535-7163.MCT-13-0870", "24523301"]}, {"Citation": "Reis LMD, et al. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. J. Biol. Chem. 2019;294:9342\u20139357. doi: 10.1074/jbc.RA119.008180.", "ArticleIdList": ["10.1074/jbc.RA119.008180", "PMC6579458", "31040181"]}, {"Citation": "Mukhopadhyay S, et al. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers. Cancer Res. 2020;80:1630\u20131643. doi: 10.1158/0008-5472.CAN-19-1363.", "ArticleIdList": ["10.1158/0008-5472.CAN-19-1363", "PMC7185043", "31911550"]}, {"Citation": "Cheng L, Wu CR, Zhu LH, Li H, Chen LX. Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor. Bioorg. Med. Chem. Lett. 2017;27:1243\u20131246. doi: 10.1016/j.bmcl.2017.01.057.", "ArticleIdList": ["10.1016/j.bmcl.2017.01.057", "28174105"]}, {"Citation": "Yeh TK, et al. Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors. J. Med. Chem. 2017;60:5599\u20135612. doi: 10.1021/acs.jmedchem.7b00282.", "ArticleIdList": ["10.1021/acs.jmedchem.7b00282", "28609101"]}, {"Citation": "Fazzari J, Singh G. Effect of glutaminase inhibition on cancer-induced bone pain. Breast Cancer. 2019;11:273\u2013282. doi: 10.2147/BCTT.S215655.", "ArticleIdList": ["10.2147/BCTT.S215655", "PMC6750878", "31571981"]}, {"Citation": "Singleton DC, et al. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer. 2020;20:470. doi: 10.1186/s12885-020-06885-3.", "ArticleIdList": ["10.1186/s12885-020-06885-3", "PMC7333265", "32450839"]}, {"Citation": "Qin X, Jiang B, Zhang Y. 4E-BP1, a multifactor regulated multifunctional protein. Cell Cycle. 2016;15:781\u2013786. doi: 10.1080/15384101.2016.1151581.", "ArticleIdList": ["10.1080/15384101.2016.1151581", "PMC4845917", "26901143"]}, {"Citation": "Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75:250\u2013263. doi: 10.1158/0008-5472.CAN-14-2789.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-2789", "PMC4299928", "25593033"]}, {"Citation": "Bhat M, et al. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 2015;14:261\u2013278. doi: 10.1038/nrd4505.", "ArticleIdList": ["10.1038/nrd4505", "25743081"]}, {"Citation": "Lin CJ, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep. 2012;1:325\u2013333. doi: 10.1016/j.celrep.2012.02.010.", "ArticleIdList": ["10.1016/j.celrep.2012.02.010", "PMC3346676", "22573234"]}, {"Citation": "Konicek BW, Dumstorf CA, Graff JR. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle. 2008;7:2466\u20132471. doi: 10.4161/cc.7.16.6464.", "ArticleIdList": ["10.4161/cc.7.16.6464", "18719377"]}, {"Citation": "Lin CJ, Malina A, Pelletier J. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res. 2009;69:7491\u20137494. doi: 10.1158/0008-5472.CAN-09-0813.", "ArticleIdList": ["10.1158/0008-5472.CAN-09-0813", "19773439"]}, {"Citation": "Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 2003;4:1\u201310. doi: 10.1186/gb-2003-4-4-210.", "ArticleIdList": ["10.1186/gb-2003-4-4-210", "PMC154570", "12702200"]}, {"Citation": "Milkereit R, et al. LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat. Commun. 2015;6:7250. doi: 10.1038/ncomms8250.", "ArticleIdList": ["10.1038/ncomms8250", "PMC4455107", "25998567"]}, {"Citation": "Broecker F, et al. Transcriptional signature induced by a metastasis-promoting c-Src mutant in a human breast cell line. FEBS J. 2016;283:1669\u20131688. doi: 10.1111/febs.13694.", "ArticleIdList": ["10.1111/febs.13694", "26919036"]}, {"Citation": "Zhang Z, Wang Y, Zhang J, Zhong J, Yang R. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol. Med. Rep. 2018;17:5037\u20135042. doi: 10.3892/mmr.2018.8533.", "ArticleIdList": ["10.3892/mmr.2018.8533", "PMC5865965", "29393423"]}, {"Citation": "Kai F, Tanner K, King C, Duncan R. Myopodin isoforms alter the chemokinetic response of PC3 cells in response to different migration stimuli via differential effects on Rho-ROCK signaling pathways. Carcinogenesis. 2012;33:2100\u20132107. doi: 10.1093/carcin/bgs268.", "ArticleIdList": ["10.1093/carcin/bgs268", "22915763"]}, {"Citation": "Smith BA, et al. Identification of genes involved in human urothelial cell\u2013matrix interactions: implications for the progression pathways of malignant urothelium. Cancer Res. 2001;61:1678\u20131685.", "ArticleIdList": ["11245483"]}, {"Citation": "Kai F, Fawcett JP, Duncan R. Synaptopodin-2 induces assembly of peripheral actin bundles and immature focal adhesions to promote lamellipodia formation and prostate cancer cell migration. Oncotarget. 2015;6:11162\u201311174. doi: 10.18632/oncotarget.3578.", "ArticleIdList": ["10.18632/oncotarget.3578", "PMC4484447", "25883213"]}, {"Citation": "Saadi I, et al. Deficiency of the cytoskeletal protein SPECC1L leads to oblique facial clefting. Am. J. Hum. Genet. 2011;89:44\u201355. doi: 10.1016/j.ajhg.2011.05.023.", "ArticleIdList": ["10.1016/j.ajhg.2011.05.023", "PMC3135813", "21703590"]}, {"Citation": "Xie J, et al. Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis. Int. J. Cancer. 2018;142:1865\u20131877. doi: 10.1002/ijc.31210.", "ArticleIdList": ["10.1002/ijc.31210", "29235102"]}, {"Citation": "Santamaria D, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811\u2013815. doi: 10.1038/nature06046.", "ArticleIdList": ["10.1038/nature06046", "17700700"]}, {"Citation": "Kayagaki N, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science. 2007;318:1628\u20131632. doi: 10.1126/science.1145918.", "ArticleIdList": ["10.1126/science.1145918", "17991829"]}, {"Citation": "DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11\u201320. doi: 10.1016/j.cmet.2007.10.002.", "ArticleIdList": ["10.1016/j.cmet.2007.10.002", "18177721"]}, {"Citation": "Ding M, et al. The mTOR targets 4E-BP1/2 restrain tumor growth and promote hypoxia tolerance in PTEN-driven prostate cancer. Mol. Cancer Res. MCR. 2018;16:682\u2013695. doi: 10.1158/1541-7786.MCR-17-0696.", "ArticleIdList": ["10.1158/1541-7786.MCR-17-0696", "29453322"]}, {"Citation": "Witkiewicz AK, et al. Targeting the vulnerability of RB tumor suppressor loss in triple-negative breast cancer. Cell Rep. 2018;22:1185\u20131199. doi: 10.1016/j.celrep.2018.01.022.", "ArticleIdList": ["10.1016/j.celrep.2018.01.022", "PMC5967622", "29386107"]}, {"Citation": "Liu JC, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018;23:112\u2013126. doi: 10.1016/j.celrep.2018.03.039.", "ArticleIdList": ["10.1016/j.celrep.2018.03.039", "PMC9357459", "29617654"]}, {"Citation": "Micalizzi DS, Ebright RY, Haber DA, Maheswaran S. Translational regulation of cancer metastasis. Cancer Res. 2021;81:517\u2013524. doi: 10.1158/0008-5472.CAN-20-2720.", "ArticleIdList": ["10.1158/0008-5472.CAN-20-2720", "PMC7854484", "33479028"]}, {"Citation": "Kenney JW, et al. Dynamics of elongation factor 2 kinase regulation in cortical neurons in response to synaptic activity. J. Neurosci. Off. J. Soc. Neurosci. 2015;35:3034\u20133047. doi: 10.1523/JNEUROSCI.2866-14.2015.", "ArticleIdList": ["10.1523/JNEUROSCI.2866-14.2015", "PMC4331626", "25698741"]}, {"Citation": "Yao Z, et al. Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells. Mol. Biosyst. 2016;12:729\u2013736. doi: 10.1039/c5mb00848d.", "ArticleIdList": ["10.1039/c5mb00848d", "26776155"]}, {"Citation": "Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 2019;15:937\u2013944. doi: 10.1038/s41589-019-0362-y.", "ArticleIdList": ["10.1038/s41589-019-0362-y", "31527835"]}, {"Citation": "Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016;535:148\u2013152. doi: 10.1038/nature18621.", "ArticleIdList": ["10.1038/nature18621", "27362227"]}, {"Citation": "Jiang Z, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J. Clin. Investig. 2010;120:3296\u20133309. doi: 10.1172/JCI41490.", "ArticleIdList": ["10.1172/JCI41490", "PMC2929714", "20679727"]}, {"Citation": "Jones RA, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J. Clin. Investig. 2016;126:3739\u20133757. doi: 10.1172/JCI81568.", "ArticleIdList": ["10.1172/JCI81568", "PMC5096803", "27571409"]}, {"Citation": "Chu HP, et al. Germline quality control: eEF2K stands guard to eliminate defective oocytes. Dev. Cell. 2014;28:561\u2013572. doi: 10.1016/j.devcel.2014.01.027.", "ArticleIdList": ["10.1016/j.devcel.2014.01.027", "PMC4712648", "24582807"]}, {"Citation": "Krieger JR, et al. Evosep one enables robust deep proteome coverage using tandem mass tags while significantly reducing instrument time. J. Proteome Res. 2019;18:2346\u20132353. doi: 10.1021/acs.jproteome.9b00082.", "ArticleIdList": ["10.1021/acs.jproteome.9b00082", "30938160"]}, {"Citation": "Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.", "ArticleIdList": ["10.1093/nar/gkv007", "PMC4402510", "25605792"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "5", "Day": "22"}, {"Year": "2021", "Month": "4", "Day": "16"}, {"Year": "2021", "Month": "4", "Day": "29", "Hour": "6", "Minute": "10"}, {"Year": "2021", "Month": "4", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "31", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "28"}], "PublicationStatus": "epublish", "ArticleIdList": ["33911160", "PMC8080725", "10.1038/s41598-021-88816-1", "10.1038/s41598-021-88816-1"]}}], "PubmedBookArticle": []}